Compare Amylx Pharmaceuticals Inc (AMLX) vs Expensify Inc (EXFY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Expensify Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Expensify Inc trades at $1.89 (market cap $182.27M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 10.9× Expensify Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Expensify Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | EXFY | |
|---|---|---|
Market Cap | $1.98B | $182.27M |
Sector | Health | Technology |
52-Week High | $18.70 | $2.33 |
52-Week Low | $7.64 | $0.75 |
Enterprise Value | $1.70B | $121.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
EXFY trades at $1.89, down 3.08% today, with a bullish technical signal from moving averages and oscillators. The company reported Q1 2026 EPS of $0.04, beating expectations, but maintains negative net income margins. Recent news highlights AI expansion and a $25 million stock buyback program, indicating management confidence despite financial challenges.
Outlook remains mixed with strong analyst buy ratings (44%) but persistent profitability issues. Key opportunities include AI product growth and cash flow stability, while risks involve sustained losses and competitive pressures. The stock presents a speculative opportunity with high volatility potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
